This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Senzaki, H. Articles by Yokote, Y. Search for Related Content PubMed PubMed Citation Articles by Senzaki, H. Articles by Yokote, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Kawasaki Disease Related Collections Chronic ischemic heart disease

(Circulation. 2001;104:860.)
© 2001 American Heart Association, Inc.

Brief Rapid Communications

Circulating Matrix Metalloproteinases and Their Inhibitors in Patients with Kawasaki Disease

Hideaki Senzaki, MD; Satoshi Masutani, MD; Jun Kobayashi, MD; Toshiki Kobayashi, MD; Hirofumi Nakano, MD; Hironori Nagasaka, MD; Nozomu Sasaki, MD; Haruhiko Asano, MD; Shunei Kyo, MD; Yuji Yokote, MD

From the Departments of Pediatric Cardiology and Pediatrics, Saitama Heart Institute, Saitama Medical School Hospital, Saitama, Japan.

Correspondence to Hideaki Senzaki, MD, Department of Pediatric Cardiology, Saitama Heart Institute, Saitama Medical School Hospital, 38 Morohongo, Moroyama, Saitama 350-0495, Japan. E-mail hsenzaki{at}saitama-med.ac.jp

Background—— Accelerated matrix breakdown caused by the increased activity of matrix metalloproteinases (MMPs) and/or the quantitative imbalance between MMP and tissue inhibitor of MMP (TIMP) have been implicated in several pathological conditions. MMP and TIMP may also be involved in the destruction of the coronary arterial wall and the resultant coronary arterial lesions in Kawasaki disease.

Methods and Results—— Plasma levels of MMPs, neutrophil elastase, and TIMPs were measured by enzyme-linked immunoassay in 57 patients with Kawasaki disease and no coronary arterial lesions (group 1) and in 8 patients with Kawasaki disease and coronary arterial lesions (group 2). Blood samples were obtained before and after intravenous gamma globulin therapy and in the convalescent stage. Levels of MMPs, neutrophil elastase, and TIMPs were significantly higher in Kawasaki disease patients before gamma globulin therapy than in 18 age-matched afebrile control subjects and 17 age-matched febrile disease control subjects (P<0.01). More importantly, the pre-gamma globulin MMP9 level and MMP9/TIMP2 ratio and post-gamma globulin MMP3 level and MMP3/TIMP1 ratio were significantly higher in group 2 than in group 1 patients (P<0.05). Although MMP levels in febrile disease controls were significantly higher than those of afebrile controls, the MMP/TIMP ratios of febrile disease controls and afebrile controls were comparable.

Conclusions—— These data suggest that patients with Kawasaki disease and high levels of MMP and/or MMP/TIMP are susceptible to coronary arterial lesions. Studies of the effects of MMP inhibitors on coronary outcome may provide evidence that MMP is a viable therapeutic target for the prevention of coronary arterial lesions due to Kawasaki disease.

Key Words: aneurysm • coronary disease • metalloproteinases

This article has been cited by other articles:

				H. Senzaki Long-Term Outcome of Kawasaki Disease Circulation, December 16, 2008; 118(25): 2763 - 2772. [Full Text] [PDF]

				M.-T. Lin, S.-J. Chen, Y.-L. Ho, K.-C. Huang, C.-A. Chen, S.-N. Chiu, L.-C. Sun, W.-J. Lee, H.-C. Chen, J.-K. Wang, et al. Abnormal Matrix Remodeling in Adolescents and Young Adults with Kawasaki Disease Late after Onset Clin. Chem., November 1, 2008; 54(11): 1815 - 1822. [Abstract] [Full Text] [PDF]

				R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]

				H Senzaki The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases Arch. Dis. Child., October 1, 2006; 91(10): 847 - 851. [Abstract] [Full Text] [PDF]

				H. Senzaki, C.-H. Chen, H. Ishido, S. Masutani, T. Matsunaga, M. Taketazu, T. Kobayashi, N. Sasaki, S. Kyo, and Y. Yokote Arterial Hemodynamics in Patients After Kawasaki Disease Circulation, April 26, 2005; 111(16): 2119 - 2125. [Abstract] [Full Text] [PDF]

				T. W. Kuijpers, M. Biezeveld, A. Achterhuis, I. Kuipers, J. Lam, C. E. Hack, A. E. Becker, and A. C. van der Wal Longstanding Obliterative Panarteritis in Kawasaki Disease: Lack of Cyclosporin A Effect Pediatrics, October 1, 2003; 112(4): 986 - 992. [Abstract] [Full Text] [PDF]

				A. Matsuyama, N. Sakai, M. Ishigami, H. Hiraoka, S. Kashine, A. Hirata, T. Nakamura, S. Yamashita, and Y. Matsuzawa Matrix Metalloproteinases as Novel Disease Markers in Takayasu Arteritis Circulation, September 23, 2003; 108(12): 1469 - 1473. [Abstract] [Full Text] [PDF]

				P. K. Chua, M. E. Melish, Q. Yu, R. Yanagihara, K. S. Yamamoto, and V. R. Nerurkar Elevated Levels of Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 during the Acute Phase of Kawasaki Disease Clin. Vaccine Immunol., March 1, 2003; 10(2): 308 - 314. [Abstract] [Full Text] [PDF]

				M. C. Dalakas Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies Neurology, December 24, 2002; 59(90126): S13 - 21. [Abstract] [Full Text]

				N. Lamblin, C. Bauters, X. Hermant, J.-M. Lablanche, N. Helbecque, and P. Amouyel Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease J. Am. Coll. Cardiol., July 3, 2002; 40(1): 43 - 48. [Abstract] [Full Text] [PDF]